Principia Biopharma Inc (PRNB)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS
*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

220 EAST GRAND AVENUE SOUTH SAN FRANCISCO, CA 94080

Principia Biopharma Inc. operates as a clinical stage biopharmaceutical company. The Company offers reversible covalent small molecule drugs for the treatment of cancers. Principia Biopharma serves patients in the United States.

Data as of 2020-09-12
Market Cap3.324 Billion Shares Outstanding33.236 Million Avg 30-day Volume2.324 Million
P/E Ratio Dividend Yield EPS-2.49
Price/Sales66.472 Price cash flow ratio48.7 Price free cash flow ratio-34.9
Book Value10.57 Price to Tangible Book9.44 Alpha0.06
Short Interest Ratio % Short Interest to Float R-squared0.081195
BETA0.859374 52-week High/Low101.89 / 25.35 Stddev0.183799
View SEC Filings from PRNB instead.
Q3 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 0 6 -100.0% 0 (0.0%) 5 (0.32%) -100.0%
Funds Holding: 9 137 -93.43% (0.0%) 47 (3.05%)
13F shares: 60.503 Thousand 31.718 Million -99.81% 15.354 Million
% Ownership 95.5115 46.2352
New Positions: 3 32 -90.63% 11
Increased Positions 1 54 -98.15% 15
Closed Positions 126 14 800.0% 46 9 411.11%
Reduced Positions 3 38 -92.11% 18
Total Calls 185 33.2 Thousand -99.44%
Total Puts 83 5.6 Thousand -98.52%
PUT/CALL Ratio 0.45 0.17 164.71% 164.71%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding PRNB (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding PRNB BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

BABLER MARTIN PRESIDENT, CEO

  • Officer
  • Director
0 2020-09-28 5

CHAI CHRISTOPHER Y CHIEF FINANCIAL OFFICER

  • Officer
0 2020-09-28 5

HARDIMAN ROY C. CHIEF BUSINESS OFFICER

  • Officer
0 2020-09-28 7

GOLDSTEIN DAVID M CHIEF SCIENTIFIC OFFICER

  • Officer
0 2020-09-28 5

WOLFF STEFANI CHIEF DEVELOPMENT OFFICER

  • Officer
0 2020-09-28 7

BECKER DANIEL J.

  • Director
0 2020-09-28 2

COLOWICK ALAN

  • Director
0 2020-09-28 4

GEORGE SIMEON

  • Director
0 2020-09-28 2

THOMAS DOLCA CHIEF MEDICAL OFFICER

  • Officer
0 2020-09-28 5

LIN SHAO-LEE

  • Director
0 2020-09-28 2

MACHADO PATRICK

  • Director
0 2020-09-28 2

TOMASELLO SHAWN

  • Director
0 2020-09-28 2

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BVF I GP LLC

BIOTECHNOLOGY VALUE FUND II LP

BVF II GP LLC

BIOTECHNOLOGY VALUE TRADING FUND OS LP

BVF PARTNERS OS LTD.

BVF GP HOLDINGS LLC

BVF INC/IL

LAMPERT MARK N

  • 10% Owner
  • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
0 2020-08-18 2

GLAXOSMITHKLINE PLC

  • FORMER 10% OWNER
2,982,855 2019-10-18 0

NEW LEAF VENTURES II, L.P.

NEW LEAF VENTURE ASSOCIATES II, L.P.

NEW LEAF VENTURE MANAGEMENT II, L.L.C.

NEW LEAF BIOPHARMA OPPORTUNITIES II, L.P.

NEW LEAF BPO ASSOCIATES II, L.P.

NEW LEAF BPO MANAGEMENT II, L.L.C

  • 10% Owner
2,325,713 2019-08-13 0

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP IV LLC

  • 10% Owner
1,605,713 2019-05-21 0

SMITHER JOHN W

  • Director
0 2019-02-19 0

GOURLAY STEVE CHIEF MEDICAL OFFICER

  • Officer
107,857 2018-09-18 0

SOFINNOVA VENTURE PARTNERS VIII, L.P.

SOFINNOVA MANAGEMENT VIII, L.L.C.

HEALY JAMES

POWELL MICHAEL

MEHRA ANAND

  • 10% Owner
2,038,208 2018-09-18 0

AKKARAJU SRINIVAS

  • Director
383,480 2018-09-18 0

SHUSTER LEWIS

  • Director
0 2018-09-13 0

MORGENTHALER VENTURE PARTNERS IX LP

MORGENTHALER MANAGEMENT PARTNERS IX, LLC

  • 10% Owner
0 2018-09-13 0

USMAN NASSIM

  • Director
  • 10% Owner
0 2018-09-13 0

THOMPSON PETER A.

  • Director
3,945 2018-09-13 0

BAKER BROS. ADVISORS LP

BAKER BROS. ADVISORS (GP) LLC

BAKER FELIX

BAKER JULIAN

  • 10% Owner
0 2018-09-13 0

SHUSTER LEWIS

SHUSTER LEWIS

  • Director
0 2018-09-13 0

AKKARAJU SRINIVAS

AKKARAJU SRINIVAS

  • Director
0 2018-09-13 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments